Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer
Canadian Urological Association Journal · 13.02.2026 · 20 (6)
DOI: 10.5489/cuaj.9398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 13.02.2026. Verfasst von Frédéric Pouliot und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre hospitalier universitaire de Québec-Université Laval, Quebec City, QC, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
We aimed to evaluate the efficacy and safety of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) following approval in the real-world Canadian clinical context.
Methods
Data on the first 50 patients with mCRPC who were treated with lutetium-177-PSMA-617 at a single center in Quebec, Canada, were retrospectively analyzed. Patients were treated with 7.4 GBq of lutetium-177-PSMA-617 administered every six weeks for up to six cycles.
Results
Median (95% confidence interval [CI]) patient age and pre-radioligand therapy prostate-specific antigen levels were 72.55 (65.92–76.77) years and 49.19 (15.61–180.65) ng/mL, respectively. Median (95% CI) time between oncologist referral for radioligand therapy and nuclear medicine consultation or first dose of lutetium-177-PSMA-617 were 12 (7.0–32.0) and 42 (28.0–54.0) days, respectively. Overall, 26.0% of patients completed six radioligand therapy cycles. Declines in prostate-specific antigen levels of 25%, 50%, and 90% were reached in 57%, 51%, and 17% of patients, after a median of two, two, and three cycles, respectively. At last followup, after a mean followup time of 8.5 months, 61% (25/41) of patients not on ongoing therapy were alive, with an estimated median overall survival of 13.0 months (95% CI 8.0–not reached).
Conclusions
Real-world data show that use of lutetium-177-PSMA-617 in patients with mCRPC is feasible in a universal healthcare system, with comparable oncologic activity to that observed in the phase 3 VISION trial. The study is limited by the short followup and its retrospective nature.
Autor:innen und Institutionen
- Centre hospitalier universitaire de Québec-Université Laval, Quebec City, QC, Canada.
- Division d'urologie, Département de chirurgie, Université Laval, Quebec City, QC, Canada.
- Division d'hématologie-oncologie, Département de médecine, Université Laval, Quebec City, QC, Canada.
- Département de radiologie et médecine nucléaire, Université Laval, Quebec City, QC, Canada.
Zitieren
APA
Pouliot, F., Lodde, M., Besançon, M., Castonguay, V., Morin-Coulombe, A., Fradet, V., Fradet, Y., Lacombe, L., Lévesque, É., Marcoux, N., Toren, P., April, G., Arsenault, F., Beaulieu, A., Singbo, N., Veilleux, C., Tremblay-Boily, M., Tremblay, V., Buteau, F. A., & Beauregard, J. M. (2026). Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer. Canadian Urological Association Journal, 20(6). https://doi.org/10.5489/cuaj.9398
Vancouver
Pouliot F, Lodde M, Besançon M, Castonguay V, Morin-Coulombe A, Fradet V, et al. Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer. Canadian Urological Association Journal. 2026;20(6). doi:10.5489/cuaj.9398
BibTeX
@article{Pouliot2026,
author = {Pouliot, Frédéric and Lodde, Michele and Besançon, Marjorie and Castonguay, Vincent and Morin-Coulombe, Antoine and Fradet, Vincent and Fradet, Yves and Lacombe, Louis and Lévesque, Éric and Marcoux, Nicolas and Toren, Paul and April, Geneviève and Arsenault, Frédéric and Beaulieu, Alexis and Singbo, Narcisse and Veilleux, Céline and Tremblay-Boily, Mélanie and Tremblay, Vincent and Buteau, François-Alexandre and Beauregard, Jean-Mathieu},
title = {Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer},
journal = {Canadian Urological Association Journal},
year = {2026},
volume = {20},
number = {6},
doi = {10.5489/cuaj.9398}
}
EUVIMED